Sign in

    Will Scheibler

    Research Analyst at Leerink Partners

    Will Scheibler is an Investment Banking Analyst at Leerink Partners, specializing in transactions across the healthcare sector. He has contributed to projects involving innovative companies in biopharma, digital health, and MedTech, though details on specific company coverage and performance metrics are not publicly available. Scheibler began his career as a Business Development Analyst at ChargeTech from 2020 to 2021 before joining Leerink Partners, where he leverages financial analysis to support capital markets activities for healthcare clients. His professional background includes hands-on experience in business development, but specific securities licenses or FINRA registrations have not been disclosed.

    Will Scheibler's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Will Scheibler's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q1 2025

    Question

    Will Scheibler, on for Joe Schwartz, asked for preliminary thoughts on paltusotine pricing, the potential impact of MFN pricing headlines, and the location of the drug's manufacturing.

    Answer

    Dr. R. Struthers, CEO, stated that final tablet manufacturing and packaging occur in the U.S., with precursors from Europe and India. Isabel Kalofonos, CCO, added that while not commenting on a specific price, the drug's value proposition is resonating well with payers. She noted no current impact from MFN headlines but confirmed they are monitoring the situation.

    Ask Fintool Equity Research AI